Wedbush Reiterates Outperform on Cogent Biosciences, Maintains $55 Price Target

Wedbush analyst David Nierengarten has reiterated an 'Outperform' rating on Cogent Biosciences (NASDAQ: COGT) and maintained a price target of $55 for the stock. No additional financial figures or strategic changes were mentioned in the article.